Valuation : Genpharmasec Limited

Market Cap 43Cr 45.51L 39.26L 36.93L 33.64L 63.26L 63.6L 4.37Cr 1.7Cr 22Cr 1.71Cr 1.67Cr 73Cr P/E 2024
-545x
P/E 2025 94.5x
Enterprise Value 42Cr 44.52L 38.4L 36.12L 32.91L 61.88L 62.22L 4.27Cr 1.66Cr 21Cr 1.67Cr 1.64Cr 71Cr EV / Sales 2024
3.47x
EV / Sales 2025 2.96x
Free-Float
56.99%
Yield 2024 *
-
Yield 2025 -
1 day+5.08%
1 week+24.00%
Current month+9.73%
1 month+20.39%
3 months+5.08%
6 months+8.77%
Current year-5.34%
1 week 0.99
Extreme 0.99
1.36
1 month 0.9
Extreme 0.9
1.36
Current year 0.75
Extreme 0.75
1.45
1 year 0.75
Extreme 0.75
2.15
3 years 0.75
Extreme 0.75
8.71
5 years 0.75
Extreme 0.75
11.08
10 years 0.75
Extreme 0.75
18
Manager TitleAgeSince
Director of Finance/CFO 39 01/11/2022
Compliance Officer - 27/03/2024
Director TitleAgeSince
Director/Board Member 57 02/01/2019
Director/Board Member 58 02/01/2019
Director/Board Member - 01/11/2022
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%+24.00%-36.08%-68.21% 68.85L
+1.97%-3.04%-15.85%+9.66% 19TCr
+1.68%+1.86%+0.43%+16.87% 12TCr
+1.24%+2.24%+13.66%+93.86% 6.32TCr
-1.89%-2.18%+26.20%+48.54% 5.2TCr
+1.51%-0.23%+0.86%-30.46% 5.1TCr
+0.42%+1.65%+21.71%-9.87% 3.4TCr
+2.18%+3.90% - - 3.08TCr
+1.69%-1.89%+40.85%-14.95% 2.38TCr
-2.97%-4.00%-7.37%+13.67% 2.34TCr
Average +1.10%+1.41%+4.93%+6.57% 5.85TCr
Weighted average by Cap. +1.19%-0.59%+1.58%+18.67%

Financials

2024 2025
Net sales 30Cr 32.04L 27.64L 26L 23.68L 44.53L 44.78L 3.07Cr 1.2Cr 15Cr 1.2Cr 1.18Cr 51Cr 34Cr 35.53L 30.65L 28.83L 26.27L 49.39L 49.66L 3.41Cr 1.33Cr 17Cr 1.33Cr 1.31Cr 57Cr
Net income -12.57L -13.24T -11.42T -10.75T -9.79T -18.41T -18.51T -1L -49.45T -6L -49.73T -48.65T -21.2L 1.23Cr 1L 1L 1L 95.9T 2L 2L 12.44L 5L 62.63L 5L 5L 2.08Cr
Net Debt -18Cr -18.85L -16.26L -15.29L -13.93L -26.2L -26.34L -1.81Cr -70.37L -9.1Cr -70.76L -69.23L -30Cr -94.03L -99.08T -85.46T -80.39T -73.24T -1L -1L -10L -4L -47.83L -4L -4L -1.59Cr
Logo Genpharmasec Limited
Genpharmasec Limited is an India-based company, which is engaged in the distribution of diagnostic pharma equipment and trading of securities. The Company’s segments include Pharmaceuticals, Trading in Securities, and Laboratory Testing. The Trading in Securities segment invests in the secondary securities market. The Company holds rights to the distribution of equipment, such as i-STAT Analyzers and its Cartridges, manufactured by Abbott Point of Care, USA, all over India. The i-STAT Analyzer is a blood analyzer used in Intensive Care Units (ICUs) of hospitals and provides test results in approximately 10 minutes. The Company’s wholly owned subsidiary includes M/s. Clinigenome India Private Limited.
Employees
10
Date Price Change Volume
02/26/02 1.240 +5.08% 34,48,139
01/26/01 ₹1.180 +4.42% 41,71,929
31/26/31 ₹1.130 +9.71% 57,30,632
28/26/28 ₹1.030 +3.00% 57,96,209
27/26/27 ₹1.000 0.00% 1,20,931
  1. Stock Market
  2. Stocks
  3. ADIRASA Stock